Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction.
about
Functional studies of BCL11A: characterization of the conserved BCL11A-XL splice variant and its interaction with BCL6 in nuclear paraspeckles of germinal center B cellsMolecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathwaysMultiple loci influence erythrocyte phenotypes in the CHARGE ConsortiumInactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphomaNext-generation prognostic assessment for diffuse large B-cell lymphomaNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewSomatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.A phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphomaLenalidomide for the treatment of B-cell lymphoma.A microarray platform-independent classification tool for cell of origin class allows comparative analysis of gene expression in diffuse large B-cell lymphomaInherited genetic variation and overall survival following follicular lymphoma.Genome Expression Pathway Analysis Tool--analysis and visualization of microarray gene expression data under genomic, proteomic and metabolic context.Model-based clustering of array CGH data.Gray zones around diffuse large B cell lymphoma. Conclusions based on the workshop of the XIV meeting of the European Association for Hematopathology and the Society of Hematopathology in Bordeaux, France.Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanismsVirtual CGH: an integrative approach to predict genetic abnormalities from gene expression microarray data applied in lymphoma.The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivoThe significance of FOXP1 in diffuse large B-cell lymphoma.Copy number variation analysis on a non-Hodgkin lymphoma case-control study identifies an 11q25 duplication associated with diffuse large B-cell lymphomaThe biology of human lymphoid malignancies revealed by gene expression profiling.A tumour suppressor network relying on the polyamine-hypusine axis.IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas.BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphomaInterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions.Bromodomain coactivators in cancer, obesity, type 2 diabetes, and inflammationPAK1 mediates resistance to PI3K inhibition in lymphomas.Refining tumor-associated aneuploidy through 'genomic recoding' of recurrent DNA copy number aberrations in 150 canine non-Hodgkin lymphomas.In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cellsAccurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues.Array-comparative genomic hybridization profiling of immunohistochemical subgroups of diffuse large B-cell lymphoma shows distinct genomic alterationsClear cell variant of diffuse large B-cell lymphoma: a case report.Identification and functional relevance of de novo DNA methylation in cancerous B-cell populations.Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma.High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy.Deregulation of COMMD1 is associated with poor prognosis in diffuse large B-cell lymphoma.Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivoGenotypic and phenotypic differences between nodal and extranodal diffuse large B-Cell lymphomas.Pathway-based analysis of the hidden genetic heterogeneities in cancers
P2860
Q21093284-7CC50623-67F3-4D29-BA30-9F2DEDF8E51AQ24652565-D86F4BB6-8A7D-4B11-8AF9-153F49FD3B69Q24655591-257A8A24-DC2B-41D5-82AC-DC09D9C56E66Q24676965-183E2F5D-BED0-44AB-9EE0-0D0551327A38Q26796428-0DA424B5-5BF7-4086-923E-27306763366CQ27304386-9AB9BBA7-FA81-4ED8-A060-317A50B27F1AQ27851546-67BB8FAA-D2ED-4A55-B0FF-AA916C9CD327Q27853399-066B1DE3-46BB-473A-80EA-F3232EA2C656Q28538467-9A4DF792-B333-4DA2-9C4D-C4D6D80BFEFCQ30249007-071DE867-3435-4973-B5A8-4552A542DF7FQ30485971-0924E2B3-DE23-41EC-A483-1E8B96993D8FQ30519549-FA018726-8034-433F-A269-C0B4224A3577Q31114440-78133E93-75FB-436D-8ABC-410B1A5A183CQ33455313-E6F0DEF2-8098-4798-9382-05DDCE1CA261Q33560762-6C1F8BC7-45F0-4673-8714-599BFF3FACCAQ33591789-C3673A53-298E-4717-87DD-B1E929EEFAB0Q33761796-531973B2-4A9B-4265-BA3D-3322FF2400BCQ33870491-B51E17B8-5C52-41CF-834E-020E02D32A4CQ33896749-370BECCE-FBC3-4A5F-9B4B-785587EF1448Q34047455-780D7B63-E284-490B-AAB4-CDB24C84C69CQ34061974-063EF046-8488-41D3-8540-D16C2ED6F2DDQ34313320-D2B11DF4-29C8-4BE6-A4AE-A7F8FA4066B6Q34313461-4D5FE9F9-54DD-4E65-958F-74F197306226Q34314178-9B3C3B33-719A-465E-88FE-12B0AD1673CCQ34339662-F08C498F-EBCE-4B9C-8721-1826DD341221Q34360414-C73638BB-E777-4F06-BF8F-CD19F3D25945Q34513460-5BCB4C65-4F5E-4018-928E-629D8BE155A1Q34539577-361D9BB3-920A-447F-B276-ABCA696568B7Q35006744-E8B8D24C-859E-4F5D-AFFD-09F4CFE54C23Q35007061-F811B73E-4DD7-43D8-9970-D890102E64B2Q35023886-CB8DC22C-BB27-45CC-85B9-53EB924AD87CQ35051460-A8D590DC-B16A-4D6E-9D76-A54852DA3FC4Q35053072-C3913F58-ED03-40FE-B7F3-E8A758B4E0CFQ35067195-A8C12C45-AC53-4A6F-B536-131400B385C1Q35080097-3F9955F1-671E-4EA5-9D65-0ED64FD56173Q35082512-F0D989C5-09E8-4474-919E-027798AD1AB3Q35119804-3372DDA4-1F87-413F-8D80-CF441449441CQ35206717-1C17D312-7591-4F0B-9E50-F35B12DE2D4FQ35440675-C7BE7CE0-8B80-4488-A32D-0F24D959E07AQ35543402-4CEB20A6-EB3F-4357-8509-5A3EACB322ED
P2860
Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Diffuse large B-cell lymphoma ...... ion-based survival prediction.
@ast
Diffuse large B-cell lymphoma ...... ion-based survival prediction.
@en
type
label
Diffuse large B-cell lymphoma ...... ion-based survival prediction.
@ast
Diffuse large B-cell lymphoma ...... ion-based survival prediction.
@en
prefLabel
Diffuse large B-cell lymphoma ...... ion-based survival prediction.
@ast
Diffuse large B-cell lymphoma ...... ion-based survival prediction.
@en
P2093
P2860
P50
P1433
P1476
Diffuse large B-cell lymphoma ...... ion-based survival prediction.
@en
P2093
Andreas Rosenwald
Andreas Zettl
Armando Lopez-Guillermo
Christof Burek
Elaine S Jaffe
Emili Montserrat
George Wright
German Ott
Hans-Konrad Muller-Hermelink
Harald Holte
P2860
P304
P356
10.1182/BLOOD-2005-04-1399
P407
P50
P577
2005-07-26T00:00:00Z